glp-1-based treatments approved for weight loss 2025 Endoscopic Sleeve Gastroplasty (ESG) and GLP-1 Therapy in 2025: A Comprehensive Guide to the Future of Bariatric Endoscopy New Weight Loss Drugs in

Management raised full-year 2026 revenue guidance by $2 billion at both the low and high ends of the range (previously the company guided for revenue of $80 billion to $83 billion

L- , , -

Key pharmacological effects include: Glucose-dependent insulin secretion Enhanced pancreatic beta-cell insulin release only when blood glucose is elevated, reducing hypoglycemia risk Suppression of glucagon secretion Decreased hepatic glucose production from pancreatic alpha cells Delayed gastric emptying Slowed movement of food from the stomach to the small intestine Central appetite regulation Reduced hunger and increased satiety through hypothalamic pathways The delayed gastric emptying effect is particularly significant and represents both a therapeutic mechanism and a potential source of adverse effects

Wood et al., 2022)